MedPath

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Eribulin-Based Regimen
Drug: nab-paclitaxel based regimen
Drug: Other Chemotherapy Regimen
First Posted Date
2023-07-20
Last Posted Date
2023-07-20
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
120
Registration Number
NCT05953909
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase 1
Conditions
Malignant Melanomas
Interventions
Drug: Recombinant Human Adenovirus Type 5 Injection
First Posted Date
2023-07-03
Last Posted Date
2023-07-10
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
10
Registration Number
NCT05928962
Locations
🇨🇳

Fujian Cancer Hospital, Department of Internal Medicine, Ward 19, Fuzhou, Fujian, China

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Phase 1
Not yet recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Drug: XH-30002 capsule
Drug: Afatiinb tablet
First Posted Date
2023-07-03
Last Posted Date
2023-07-03
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
20
Registration Number
NCT05927844

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Phase 2
Not yet recruiting
Conditions
Gastrointestinal Tumors
Interventions
Combination Product: Anti-allergic treatment
First Posted Date
2023-06-28
Last Posted Date
2023-06-28
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
500
Registration Number
NCT05922358

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Phase 2
Recruiting
Conditions
Carcinoma
Cervix Carcinoma
Interventions
Drug: Karelizumab combined with etoposide and cisplatin
First Posted Date
2023-06-18
Last Posted Date
2024-03-06
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05910177
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Phase 2
Not yet recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
First Posted Date
2023-06-09
Last Posted Date
2023-06-13
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05897138

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase 1
Not yet recruiting
Conditions
Small Cell Lung Cancer
Interventions
Drug: Surufatinib,Serplulimab,Etoposide,Carboplatin
First Posted Date
2023-05-31
Last Posted Date
2023-05-31
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
39
Registration Number
NCT05882630
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

First Posted Date
2023-05-03
Last Posted Date
2023-11-15
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
20
Registration Number
NCT05839470
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
Conditions
Health Related Quality of Life
Tyrosine Kinase Inhibitor
Thyroid Cancer
Interventions
Drug: Tyrosine kinase inhibitor drugs.
First Posted Date
2023-04-21
Last Posted Date
2023-04-21
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
80
Registration Number
NCT05824312
Locations
🇨🇳

Road Fuma No.420, Fuzhou, Fujian, China

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Phase 2
Not yet recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Tislelizumab
Drug: Irinotecan Hydrochloride
Drug: cetuximab
Radiation: SBRT
First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
23
Registration Number
NCT05799443
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy